Systematix

Institutional Equities

NMDC 10 February 2025

Margin expansion despite EBITDA miss on higher royalty expense

NMDC reported 3QFY25 EBITDA of Rs 23.7bn (+18%/+71% YoY/QoQ), 14% below our estimate due to higher royalty payments during the quarter, in line with higher production. Iron ore (IO) production and sales volumes for the quarter came in at 13.3mt (+8.7% YoY, +60.5% QoQ) and 11.9mt (+4.8% YoY, +22.6% QoQ), respectively. Realisations for 3QFY25 averaged Rs 5,501/t (+15.9%/+8.9% YoY/QoQ), 1% below our estimate of Rs 5,550/t. EBITDA margin for the quarter was 36.1% versus 37.1%/28.2% in 3QFY24/2QFY25. Cost of production excl. selling expenses and royalty stood at Rs 864/t (+1.0%/-48.6% YoY/QoQ). Employee costs per ton decreased to Rs 368 this quarter vs Rs 430 in 2QFY25. NMDC implemented a price cut in January, declining lump and fines prices by 6% each to Rs 6,000/ Rs 5,060 per ton vs Rs 6,350/Rs 5,750 per ton in October 2024, respectively. The company is looking at strong volume recovery in 4Q and is confident of securing EC limit enhancements this month and next. NMDC has also outlined a Rs 700bn capex plan to reach the 100mt volume target by 2030; finer details of the plan remain to be shared. We maintain HOLD rating on the stock based on 6x FY27E EV/EBITDA. Delays in securing EC enhancement and geopolitical factors causing a downward biased movement in IO prices are key risks for the company.

Valuation and view: NMDC's dispatches have dropped by 1% YoY to 31.8mt in 9MFY25. We expect a 4% growth in dispatches in FY25, with 4Q estimated to record a substantial 16% YoY growth to 14.6mt. NMDC's resilient production compared to sluggish dispatches highlights persistent bottlenecks in evacuation capacity. The impact of flattish volumes has largely been offset by higher iron ore prices, not falling in line with a weak global outlook and the commensurate fall in steel prices. We expect downward price revisions in the near to medium term till adequate demand factors are in place. However, successful EC limit enhancements would drive volume growth in the near term. We revise our FY25/FY26 EBITDA estimates by +9%/+5% on higher volume assumptions and keep FY27 estimates unchanged. We estimate 46.3mt/50.7mt/52.2mt volume sales for FY25/FY26/FY27 and value NMDC at 6x FY27E EV/EBITDA with a revised target price of Rs 70/share. The company, in its vendor meeting last month, announced a Rs 700bn capex plan over the next 5-6 years to reach the targeted 100mt volume mark. The number translates to an annual rate of over Rs 120bn versus the current annual capex of Rs 40bn. We believe the plan lacks sufficient clarity at this point. Our target price of Rs 70/share (Rs 80/share earlier), implies an 11% upside from CMP, thereby we maintain HOLD rating on the stock.

Key highlights of the 3QFY25 earnings call

- Capex: The company has incurred a capex of Rs 31bn to date and expects to close
 FY25 with a total spend of Rs 40bn. It has outlined a capex plan of Rs 700bn over
 the next 5-6 years to achieve a capacity of 100mt. While the company has not
 disclosed a detailed capex breakdown, it indicated that investments will be
 directed toward enhancing dispatch capacities, including logistics and evacuation
 infrastructure, slurry pipelines, rakes, and conveyors.
- **Guidance:** Management expects stronger volumes in 4QFY25 and guides for 53mt and 60mt volumes for FY26 and FY27, respectively.

RESULT UPDATE Sector: Metals Rating: HOLD CMB: Rs 64 Target Price: Rs 70

CIVIP: RS 64	rarget Price: RS 70
Stock Info	
Sensex/Nifty	77,312/ 23,382
Bloomberg	NMDC IN
Equity shares (mn)	8,792
52-wk High/Low	Rs 95/60
Face value	Rs 1
M-Cap	Rs 563bn/USD 6.8bn


Financial Snapshot (Rs bn)

Y/E Mar	FY25E	FY26E	FY27E
Sales	246.8	260.3	267.8
EBITDA	81.8	83.1	87.1
PAT	64.4	56.0	55.9
EPS (Rs)	7.3	6.4	6.4
PE (x)	8.7	10.0	10.1
EV/EBITDA (x)	5.5	5.4	5.1
RoE (%)	23%	17%	15%
RoCE (%)	26%	21%	19%
Dividend yield (%)	4.0%	3.5%	3.5%

Shareholding Pattern (%)

	Dec'24	Sep'24	Jun'24
Promoter	60.8	60.8	60.8
-Pledged	0.0	0.0	0.0
FII	12.1	12.6	12.8
DII	14.5	14.1	14.3
Others	12.6	12.5	12.1

Stock Performance (1-year)



Shweta Dikshit shwetadikshit@systematixgroup.in +91 22 6704 8042

Hinal Kothari

hinalkothari@systematixgroup.in +91 22 6704 8076

Systematix Research is also available on Bloomberg SSSL <Go>, Thomson & Reuters

• **Project updates:** Management expects to commission the 2mt pellet plant by end-CY25, with provisions for upgrading it to 6mt as part of the Rs 700bn capex plan.

- EC limit enhancement: NMDC's EC limit enhancement is advancing, with approvals for Deposit 5 (2mt), a key iron ore reserve in Bailadila, Chhattisgarh, expected by month-end or mid-next month. Deposit 14, another major reserve in the region, is in the final approval stages. These clearances are crucial for NMDC's expansion, enabling higher extraction volumes and supporting its 100mt output target by 2030.
- Rashtriya Ispat Nigam Limited (RINL) dues: The company has allocated Rs 15bn for land acquisition from RINL, primarily for developing a slurry pipeline, pellet plant, and grinding yard. The company has taken land possession and initiated boundary construction, with further project execution now underway. Additionally, RINL has initiated supplier payments following the Rs 110bn Gol grant, which is expected to improve payments of outstanding dues.
- NMDC steel and availability of rakes: NMDC Steel reported production of ~360kt, with rake availability remaining a key bottleneck. The company is addressing this by engaging with Indian Railways and exploring procurement from private suppliers. Management expects NMDC Steel to achieve breakeven once rake constraints are resolved, likely by 1QFY26.


Exhibit 1: Quarterly snapshot

(Rs bn)	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Net revenues	54	65	54	49	66
YoY change (%)					21%
QoQ change (%)					34%
Expenditure	34	44	31	35	42
EBITDA	20	21	23	14	24
YoY change (%)					18%
QoQ change (%)					71%
EBITDA Margin (%)	37	32	43	28	36
Adj. PAT	17	14	20	12	19
YoY change (%)					10%
QoQ change (%)					59%

Exhibit 2: NMDC's realisation trend for lumps and fines

9,000 - 7,000 - 6,000 - 7,000 - 6,000 - 7,000 - 6,000 - 7,000

Exhibit 3: Comparison with benchmark iron ore prices




Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 4: Discount to international prices has contracted recently



Exhibit 5: Dispatch volumes trend higher sequentially



Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 6: YoY/QoQ change in quarterly dispatch volumes





Exhibit 7: Quarterly average NSR trend



Source: Company, Systematix Institutional Research

Exhibit 8: YoY/QoQ change in quarterly average NSR

150% 100% 50% 0% -50% -100% 1QFY24 1QFY21 2QFY21 3QFY21 4QFY21 1QFY22 LQFY23 **2QFY24** 3QFY24 ■ QoQ Change ■ YoY change in avg. iron ore NSR


Source: Company, Systematix Institutional Research

Exhibit 9: Quarterly EBITDA/t




Source: Company, Systematix Institutional Research

Exhibit 10: YoY change in quarterly EBITDA/t




Source: Company, Systematix Institutional Research

Exhibit 11: Cost of production at USD 37/t (+12%/-27% YoY/QoQ)



Source: Company, Systematix Institutional Research

Exhibit 12: YoY change in CoP



Source: Company, Systematix Institutional Research

Exhibit 13: Annual dispatch to pick up with EC limit enhancement





Exhibit 14: Revenue growth in line with higher volumes

80% 300 60% 250 37% 40% .9% 15% 200 20% 150 0% -20% 100 -40% 50 -60% FY25E FY27E FY16 FY20 FY21 FY17 Revenue (Rs bn) YoY Growth (RHS)


Source: Company, Systematix Institutional Research

Exhibit 15: EBITDA trend



Source: Company, Systematix Institutional Research

Exhibit 16: EBITDA/t




Source: Company, Systematix Institutional Research

Exhibit 17: Profit after tax



Source: Company, Systematix Institutional Research

Exhibit 18: RoE and RoCE trend



Source: Company, Systematix Institutional Research

Exhibit 19: Working capital cycle





Exhibit 20: Cash generation and capex cycle

70 57 55 54 60 52 50 36 40 30 21 2120 20 10 0 -10 -20 FY16 FY17 FY27E FY25E FCF (Rs bn) ■ Capex (Rs bn)


Exhibit 21: China IO imports prices



Source: Company, Systematix Institutional Research


Source: Bigmint, Systematix Institutional Research

Exhibit 22: iron ore imports to China have increased by 11% MoM in Dec'24




Source: Company, Systematix Institutional Research

Exhibit 23: Production of iron ore in China increased by 5% MoM



Source: Company, Systematix Institutional Research

Exhibit 24: Production of iron ore in India increased by 3% MoM



NMDC 10 February 2025

Exhibit 25: Key assumptions

	FY22	FY23	FY24	FY25E	FY26E	FY27E
Iron ore production volume (mt)	41	38	45	46	51	52
Iron ore sales volume (mt)	41	38	45	46	51	52
Avg. iron ore realization (USD/t)	79	48	54	63	61	63
Avg. iron ore realization (Rs/t) (Incl. Royalty)	5,875	3,781	4,543	5,330	5,138	5,131
EBITDA/tonne (Rs/t)	3,096	1,582	1,634	1,766	1,641	1,670
EBITDA/tonne (USD/t)	42	20	20	21	19	21
Cost/tonne (USD/t)	37	28	35	42	41	43

Source: Systematix Institutional Research

Exhibit 26: NMDC Valuation: EV/EBITDA method (FY27E)

	Discount	Particulars	Multiple	Ent. value	Per share
	(%)	(Rs bn)	(x)	(Rs bn)	(Rs)
EBITDA		87.1	6.0	523	59
Net cash (Current)		77	1.00	77	9
Add: CWIP (1HFY25)		38	0.50	19	2
Target price per share				70	

Source: Systematix Institutional Research

Exhibit 27: Revised estimates

Previous			Revised			% Change			
(Rs bn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	230	247	261	247	260	268	7%	5%	3%
EBITDA	75	79	87	82	83	87	9%	5%	0%
PAT	50	55	60	64	56	56	29%	2%	-7%
Avg. iron ore realization (USD/t)	59	60	63	63	61	63	8%	2%	1%
Iron ore sales volume (mt)	46	49	51	46.3	50.7	52.2	1%	3%	2%

NMDC 10 February 2025

FINANCIALS (CONSOLIDATED)

Profit & Loss Statement

YE: Mar (Rs bn)	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	177	213	247	260	268
Expenditure	116	140	165	177	181
EBITDA	61	73	82	83	87
Depreciation	3	4	5	9	13
EBIT	57	69	77	74	74
Interest and other income	7	13	13	1	1
Exceptionals	(12)	3	-	-	-
PBT	76	80	89	75	75
Taxes	21	24	25	19	19
Adj. PAT	65	54	64	56	56
No of shares	2,931	2,931	8,792	8,792	8,792
Adj. EPS	22.1	18.3	7.3	6.4	6.4

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs bn)	FY23	FY24	FY25E	FY26E	FY27E
Equity capital	3	3	3	3	3
Reserves and surplus	223	254	309	357	405
Net worth	226	257	312	360	408
Debt	21	34	29	27	26
Other liabilities	23	33	33	33	33
Total liabilities and equity	300	357	410	456	504
Inventories	27	28	31	33	32
Debtors	44	35	44	45	44
Cash and bank	71	124	128	128	137
Loans and advances	5	3	3	3	3
Total current assets	176	215	232	235	243
Net block	30	25	62	105	146
CWIP	20	32	32	32	32
Investments	9	10	10	10	10
Current liabilities	59	84	82	80	80
Provisions	14	16	16	16	16
Net deferred tax	3	3	3	3	3
Other assets	21	33	36	36	36
Total assets	300	357	410	456	504

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs bn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	76	80	89	75	75
Add: Depreciation	3	4	5	9	13
Add: Interest	(5)	(10)	(13)	(1)	(1)
Less: taxes paid	(21)	(18)	(25)	(19)	(19)
Add: Other adjustments	1	1	0	0	0
Less: WC changes	(36)	19	(9)	(3)	3
Total OCF	18	74	47	62	71
OCF w/o WC changes	55	55	57	64	68
Capital expenditure	(12)	(18)	(42)	(52)	(54)
Change in investments	0	(0)	-	-	-
Interest/Dividend Recd	6	10	13	1	1
Total ICF	2	(61)	(29)	(52)	(53)
Free Cash Flows	6	55	6	9	18
Dividend payment	(11)	(25)	(9)	(8)	(8)
Change in borrowings	(1)	(0)	-	-	-
Buyback	-	-	-	-	-
Total Financing CF	(21)	(13)	(14)	(10)	(9)
Net change in cash	(0)	0	4	0	9
Opening cash & CE	1	1	1	5	5
Closing cash & CE	1	1	5	5	15

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY23	FY24	FY25E	FY26E	FY27E
YoY growth in Revenue	-32%	21%	16%	5%	3%
YoY growth in EBITDA	-52%	20%	12%	2%	5%
YoY growth in Net income	-32%	-17%	20%	-13%	0%
EBITDA margin	34%	34%	33%	32%	33%
PAT margin	37%	25%	26%	22%	21%
ROE	32%	22%	23%	17%	15%
ROCE	26%	27%	26%	21%	19%
Net debt to equity (x)	(0.22)	(0.35)	(0.32)	(0.28)	(0.27)
Per share numbers (Rs)					
Reported earnings	22.1	18.3	7.3	6.4	6.4
Dividend	6.6	6.6	2.6	2.2	2.2
Free cash	2.0	18.9	0.6	1.1	2.0
Book value	77	88	35	41	46
Valuations (x)					
P/E	2.9	3.5	8.7	10.0	10.1
EV/EBITDA	7.4	6.1	5.5	5.4	5.1
EV to sales	2.5	2.1	1.8	1.7	1.7
P/B	2.5	2.2	1.8	1.6	1.4

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, Shweta Dikshit, Hinal Kothari; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited (SSSIL) or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

- II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:
 - 1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
 - 2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
 - 3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
 - 4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
 - 5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
 - 6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
 - 7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
 - 8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
 - 9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.





Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell: grievance@systematixgroup.in

Details of Registration: CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI: ARN - 64917